메뉴 건너뛰기




Volumn 31, Issue 48, 2013, Pages 5745-5753

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study

Author keywords

HPV vaccination; HPV 16 18 AS04 adjuvanted vaccine; Human immunodeficiency virus (HIV); Human papillomavirus (HPV); Immunogenicity; Safety

Indexed keywords

ANTIGEN; PLACEBO; VIRUS ANTIBODY; WART VIRUS VACCINE;

EID: 84886947596     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.032     Document Type: Article
Times cited : (87)

References (30)
  • 4
    • 78049528352 scopus 로고    scopus 로고
    • Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
    • de Sanjose S., Quint W.G.V., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
    • (2010) Lancet Oncol , vol.11 , pp. 1048-1056
    • de Sanjose, S.1    Quint, W.G.V.2    Alemany, L.3    Geraets, D.T.4    Klaustermeier, J.E.5    Lloveras, B.6
  • 5
    • 0033518608 scopus 로고    scopus 로고
    • Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women
    • Palefsky J.M., Minkoff H., Kalish L.A., Levine A., Sacks H.S., Garcia P., et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999, 91:226-236.
    • (1999) J Natl Cancer Inst , vol.91 , pp. 226-236
    • Palefsky, J.M.1    Minkoff, H.2    Kalish, L.A.3    Levine, A.4    Sacks, H.S.5    Garcia, P.6
  • 6
    • 47749135917 scopus 로고    scopus 로고
    • Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women
    • Denny L., Boa R., Williamson A.L., Allan B., Hardie D., Ress S., et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women. Obstet Gynecol 2008, 111:1380-1387.
    • (2008) Obstet Gynecol , vol.111 , pp. 1380-1387
    • Denny, L.1    Boa, R.2    Williamson, A.L.3    Allan, B.4    Hardie, D.5    Ress, S.6
  • 7
    • 50649110466 scopus 로고    scopus 로고
    • Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening
    • Kahesa C., Mwaiselage J., Wabinga H.R., Ngoma T., Kalyango J.N., Karamagi C.A. Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening. BMC Public Health 2008, 8:262.
    • (2008) BMC Public Health , vol.8 , pp. 262
    • Kahesa, C.1    Mwaiselage, J.2    Wabinga, H.R.3    Ngoma, T.4    Kalyango, J.N.5    Karamagi, C.A.6
  • 8
    • 67650458435 scopus 로고    scopus 로고
    • Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women
    • Singh D.K., Anastos K., Hoover D.R., Burk R.D., Shi Q., Ngendahayo L., et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009, 199:1851-1861.
    • (2009) J Infect Dis , vol.199 , pp. 1851-1861
    • Singh, D.K.1    Anastos, K.2    Hoover, D.R.3    Burk, R.D.4    Shi, Q.5    Ngendahayo, L.6
  • 11
    • 84886946976 scopus 로고    scopus 로고
    • UNAIDS Report on the Global AIDS Epidemic [accessed 11.7.12].
    • UNAIDS Report on the Global AIDS Epidemic 2010. [accessed 11.7.12]. http://www.unaids.org/globalreport/Global_report.htm.
  • 12
    • 33745290276 scopus 로고    scopus 로고
    • HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study
    • Moodley J.R., Hoffman M., Carrara H., Allan B.R., Cooper D.D., Rosenberg L., et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer 2006, 6:135.
    • (2006) BMC Cancer , vol.6 , pp. 135
    • Moodley, J.R.1    Hoffman, M.2    Carrara, H.3    Allan, B.R.4    Cooper, D.D.5    Rosenberg, L.6
  • 13
    • 8444249386 scopus 로고    scopus 로고
    • Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
    • Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
    • (2004) Lancet , vol.364 , pp. 1757-1765
    • Harper, D.M.1    Franco, E.L.2    Wheeler, C.3    Ferris, D.G.4    Jenkins, D.5    Schuind, A.6
  • 14
    • 33646058566 scopus 로고    scopus 로고
    • Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
    • Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
    • (2006) Lancet , vol.367 , pp. 1247-1255
    • Harper, D.M.1    Franco, E.L.2    Wheeler, C.M.3    Moscicki, A.B.4    Romanowski, B.5    Roteli-Martins, C.M.6
  • 15
    • 34250850161 scopus 로고    scopus 로고
    • Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
    • Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
    • (2007) Lancet , vol.369 , pp. 2161-2170
    • Paavonen, J.1    Jenkins, D.2    Bosch, F.X.3    Naud, P.4    Salmerón, J.5    Wheeler, C.M.6
  • 16
    • 67651049056 scopus 로고    scopus 로고
    • Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
    • Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
    • (2009) Lancet , vol.374 , pp. 301-314
    • Paavonen, J.1    Naud, P.2    Salmerón, J.3    Wheeler, C.M.4    Chow, S.N.5    Apter, D.6
  • 17
    • 71649087760 scopus 로고    scopus 로고
    • Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
    • GlaxoSmithKline Vaccine HPV-007 Study Group
    • GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
    • (2009) Lancet , vol.374 , pp. 1975-1985
  • 18
    • 84855300842 scopus 로고    scopus 로고
    • Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    • Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
    • (2012) Lancet Oncol , vol.13 , pp. 89-99
    • Lehtinen, M.1    Paavonen, J.2    Wheeler, C.M.3    Jaisamrarn, U.4    Garland, S.M.5    Castellsagué, X.6
  • 19
    • 84855309413 scopus 로고    scopus 로고
    • Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    • Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
    • (2012) Lancet Oncol , vol.13 , pp. 100-110
    • Wheeler, C.M.1    Castellsagué, X.2    Garland, S.M.3    Szarewski, A.4    Paavonen, J.5    Naud, P.6
  • 20
    • 84886954027 scopus 로고    scopus 로고
    • WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization
    • WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization, 2007.
    • (2007)
  • 21
    • 84886950890 scopus 로고    scopus 로고
    • Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. World Health Organization
    • Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. World Health Organization, 2006.
    • (2006)
  • 22
    • 84886950785 scopus 로고    scopus 로고
    • Provincial Administration Western Cape. Antiretroviral Treatment Protocol. Version 2, April
    • Provincial Administration Western Cape. Antiretroviral Treatment Protocol. Version 2, April 2004.
    • (2004)
  • 23
    • 56149091686 scopus 로고    scopus 로고
    • Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
    • Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccine 2008, 4:425-434.
    • (2008) Hum Vaccine , vol.4 , pp. 425-434
    • Dessy, F.J.1    Giannini, S.L.2    Bougelet, C.A.3    Kemp, T.J.4    David, M.P.5    Poncelet, S.M.6
  • 24
    • 84855181757 scopus 로고    scopus 로고
    • Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years
    • Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccine 2011, 7:1343-1358.
    • (2011) Hum Vaccine , vol.7 , pp. 1343-1358
    • Einstein, M.H.1    Baron, M.2    Levin, M.J.3    Chatterjee, A.4    Fox, B.5    Scholar, S.6
  • 25
    • 67651031934 scopus 로고    scopus 로고
    • Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention. A pooled analysis of 11 clinical trials
    • Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention. A pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:332-340.
    • (2009) Hum Vaccin , vol.5 , pp. 332-340
    • Descamps, D.1    Hardt, K.2    Spiessens, B.3    Izurieta, P.4    Verstraeten, T.5    Breuer, T.6
  • 26
    • 70049106412 scopus 로고    scopus 로고
    • Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions
    • van den Berg R., van Hoogstraten I., van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 2009, 11:157-164.
    • (2009) AIDS Rev , vol.11 , pp. 157-164
    • van den Berg, R.1    van Hoogstraten, I.2    van Agtmael, M.3
  • 27
    • 35349028297 scopus 로고    scopus 로고
    • GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives
    • Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
    • (2007) Expert Rev Vaccines , vol.6 , pp. 723-739
    • Garçon, N.1    Chomez, P.2    Van Mechelen, M.3
  • 28
    • 0029201182 scopus 로고
    • Monophosphoryl lipid A as an adjuvant, Past experiences and new directions
    • Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant, Past experiences and new directions. Pharm Biotechnol 1995, 6:495-524.
    • (1995) Pharm Biotechnol , vol.6 , pp. 495-524
    • Ulrich, J.T.1    Myers, K.R.2
  • 30
    • 33746096523 scopus 로고    scopus 로고
    • Enhanced humoral and memory B-cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminum salt combination (AS04) compared to aluminum salt only
    • Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B-cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminum salt combination (AS04) compared to aluminum salt only. Vaccine 2006, 24:5937-5949.
    • (2006) Vaccine , vol.24 , pp. 5937-5949
    • Giannini, S.L.1    Hanon, E.2    Moris, P.3    Van Mechelen, M.4    Morel, S.5    Dessy, F.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.